Pharmaceutical Network November 19th News At the time of the R & D Center for ten years，Roche announced that it will invest in 136 million Swiss franc (about 863 million yuan) to build a new R & D Shanghai Innovation Center，Further help the company to explore and develop world -class innovative drugs in the field of infectious diseases。

 

The innovation center is planned to be completed in 2018，It will effectively promote cooperation between Roche and local scientific research institutions，To better solve the huge medical needs in the field of infectious diseases。As an important strategic deployment as Roche，Roche Shanghai Innovation Center will be equipped with world -class research equipment and attracts the world's top scientific research talents.，Continuously strengthen Roche's ability stake online sports bettingstake betting appto develop innovative drugs for global patients in China，Reflect that its continuous deepening & quot; China R & D & Quot; long -term commitment。

 

Roche Global Pharmaceutical Research and Early Development Dr. John C. Reed said when attending the 10th anniversary of the founding of Roche R & D (China) Co., Ltd.: & quot; China has important strategic significance for Roche global research and development。Establishment of Roche Shanghai Innovation Center，It will open up a new chapter in Roche China，It will also further help us develop the world's leading breakthrough drugs in China。As a family based on research and development，Health Medical Company driven by innovation，As early as 2004, Roche established the first R & D center of the first multinational pharmaceutical factory in Shanghai-Roche R & D (China) Co., Ltd.。In the past ten years，We have trained an excellent cross -domain research and development team，Developed the potential new drug product line。Future，We will pass this innovation center，Continue to develop excellent innovative drugs for patients with Asia and global patients，Solve the unrealized needs of patients in the field of infectious diseases。& quot;

 

& quot; China R & D & Quot;，Help Global

 

Chronic hepatitis B hepatitis、Infectious diseases such as influenza and polys resistance bacterial infections are challenges facing the world in the world。China as a country with high incidence of such diseases，Disease prevention and treatment has always been the top priority of national medical and health work。In China，Only those who have chronic infection of hepatitis B virus are more than stake sports betting app80 My stake betting appmillion people。At the same time，As a big country with a population over one billion，China is influenza，The prevention and control of cross -border infectious diseases such as avian influenza also faces huge challenges。Not only that，More and more resistant to the emergence of drug -resistant bacteria，Causes bacterial infection to produce resistance to common antibiotics，Questions need to be solved urgently。So，The industry needs to develop a more innovative solution to cope with this severe challenge。

 

Roche R & D (China) Co., Ltd. is the only research on anti -infective diseases，A multinational company R & D institution with the overall value chain of drug research and clinical development。Dr. Janet Hammond, senior vice president of global infection disease research and transformation of Roche said: & quot; Roche is committed to continuously exploring and developing innovative drugs，To better meet the urgent needs of Chinese and global patients in the field of infectious diseases。Roche R & D (China) Co., Ltd. is one of Roche's worldwide in the field of infectious diseases from early drug research to later clinical trials.。With the establishment of the new Shanghai Innovation Center Experimental Building，We hope to accelerate and improve the ability to develop first -class drugs，To meet the needs of patients。& quot;

 

New facilities, new vision

 

The new innovation center will take Shanghai as the headquarters，Equipped with world -class experimental equipment，Help Roche Shanghai R & D personnel to carry out new drug research and development。The area will reach 14 after the completion of the new stake sports betting appcenter,stake sports betting app000 square meter，With 220 modular work areas。

 

Dr. Xu Xiaoxing, general manager of Roche R & D (China) Co., Ltd. said: & quot; China is an important part of Roche's global R & D strategy。Thanks to the support of the partners of all parties，Our research and development center's research in the field of anti -infective diseases has achieved staged fruitful results。With the continuous expansion and development of our clinical trial items，We look forward to partners with China、Government agencies carry out closer cooperation，The research of local scientists has been transformed into innovative drugs with more efficiently，Breeding patients in China and even the world。& quot;

 

About Roche Global

 

Roche Headquarters is located in Basel, Switzerland，Is a global health medical company based on research and development，With the world's leading pharmaceutical and diagnostic business。As the world's largest biotechnology company，Roche in anti -tumor、Immune、Anti -infection、Ophthalmology and central nervous system has first -class differentiated drugs。Roche enjoys leadership in the field of global in vitro diagnosis and tissue -based oncology diagnosis，It is also a pioneer in the field of diabetes management。The individual medical care advocated by Roche aims to pass the drug and diagnosis，Significant improvement of human health、The quality of life and the survival period of patients。Roche was founded in 1896，One century has made important contributions to the global health cause。In the Basic Drug Catalog of the World Health Organization，Drugs Stake Sports Bettingstake sports betting appdeveloped by 24 Roche，Including antibiotics used to save life、Anti -malaria and chemotherapy drugs。

 

2013，Roche global employees exceed 85,000，R & D investment over 8.7 billion Swiss franc，Sales reached 46.8 billion Swiss franc。Genentech is the wholly -owned subsidiary of the Roche Group。In addition，Roche is also the controller of the Japanese Sino -Foreign Pharmaceutical Co., Ltd.。